Evidence map›Paper›PMID 34375748›Full record

ArticleContemporary clinical trials2021

Multilevel Follow-up of Cancer Screening (mFOCUS): Protocol for a multilevel intervention to improve the follow-up of abnormal cancer screening test results.

Jennifer S Haas, Steven J Atlas, Adam Wright, E John Orav, David G Aman, Erica S Breslau, Timothy E Burdick, Emily Carpenter, Frank Chang, Tin Dang and 13 more

Registry-linked trialOpen access · greenAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03979495 (mFOCUS), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03979495 nacompletednot on this map

mFOCUS (Multilevel FOllow-up of Cancer Screening)

TypeinterventionalSponsorMassachusetts General HospitalRan2020 to 2022Enrolled11,980ConditionsCancerArmsmFOCUS
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Jennifer S HaasDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: Jennifer.Haas@mgh.harvard.edu.
Steven J AtlasDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Adam WrightDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.
E John OravDivision of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.
David G AmanInformation, Technology and Consulting (ITC), Dartmouth College, Lebanon, NH.
Erica S BreslauDivision of Cancer Prevention and Control, National Cancer Institute, Rockville, MD, USA.
Timothy E BurdickDepartment of Community and Family Medicine, Dartmouth-Hitchcock Health, Lebanon, NH; The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Hanover, NH, USA.
Emily CarpenterDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Frank ChangDivision of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.
Tin DangDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Courtney J DiamondDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sarah FeldmanDepartment of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA.
Kimberly A HarrisDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Shoshana J HortDepartment of Medicine, Dartmouth-Hitchcock Health, Lebanon, NH, USA.
Molly L HousmanThe Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Hanover, NH, USA.
Amrita MeckerDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Constance D LehmanDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sanja Percac-LimaDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Rebecca SmithThe Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Hanover, NH, USA.
Amy J WintDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jie YangDivision of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.
Li ZhouDivision of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.
Anna N A TostesonThe Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Hanover, NH, USA; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Brigham and Women's Hospital · USMassachusetts General Hospital · USHarvard University · USDartmouth Institute for Health Policy and Clinical Practice · USNational Cancer Institute · USVanderbilt University Medical Center · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Promoting follow-up of abnormal cancer screening tests using population-basedsystems to support stepped care multilevel interventionU01CA225451 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ATLAS, STEVEN J, HAAS, JENNIFER S · 2018 to 2022
$4.2M
NCI NIH HHS P30 CA023108NCI NIH HHS U01 CA225451
6 · The paper itself

Abstract

introductionWhile substantial attention is focused on the delivery of routine preventive cancer screening, less attention has been paid to systematically ensuring that there is timely follow-up of abnormal screening test results. Barriers to completion of timely follow-up occur at the patient, provider, care team and system levels.

methodsIn this pragmatic cluster randomized controlled trial, primary care sites in three networks are randomized to one of four arms: (1) standard care, (2) "visit-based" reminders that appear in a patient's electronic health record (EHR) when it is accessed by either patient or providers (3) visit based reminders with population health outreach, and (4) visit based reminders, population health outreach, and patient navigation with systematic screening and referral to address social barriers to care. Eligible patients in participating practices are those overdue for follow-up of an abnormal results on breast, cervical, colorectal and lung cancer screening tests.

resultsThe primary outcome is whether an individual receives follow-up, specific to the organ type and screening abnormality, within 120 days of becoming eligible for the trial. Secondary outcomes assess the effect of intervention components on the patient and provider experience of obtaining follow-up care and the delivery of the intervention components.

conclusionsThis trial will provide evidence for the role of a multilevel intervention on improving the follow-up of abnormal cancer screening test results. We will also specifically assess the relative impact of the components of the intervention, compared to standard care.

trial registrationClinicalTrials.gov NCT03979495.

Indexed as

Lung NeoplasmsPatient NavigationEarly Detection of CancerFollow-Up StudiesHumansMass ScreeningPragmatic Clinical Trials as TopicRandomized Controlled Trials as TopicCancer preventionCancer screeningMultilevel intervention

Identifiers

PMID34375748
PMCPMC8900526
OpenAlexW3192782474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.